Vertex Pharma stock after-hours at EUR 446.63: minus 0.62 percent versus prior close
Published on 10/06/2026 at 20:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharma was at EUR 446.63 in after-hours trading at 8:31 p.m. CEST on October 6, 2026, down 0.62 percent versus the prior close of EUR 449.43 at Lang & Schwarz. The bid was EUR 446.55 and the ask was EUR 446.70. The real-time quote of Vertex Pharma stock remains continuously updated through the after-hours session.
Trading day in Frankfurt
The Lang & Schwarz price reflects the German trading venue’s euro quote and is stated separately from Vertex’s company announcement. The reference price is the Lang & Schwarz prior close of EUR 449.43.
Inaxaplin study update
In a September 22, 2026 release, Vertex Pharmaceuticals Incorporated said its Phase 2b AMPLIFIED study of inaxaplin produced a 42.7 percent reduction in urine albumin-to-creatinine ratio at Week 13 from baseline among people with APOL1-mediated kidney disease and modest proteinuria. In a cohort involving people with the disease and type 2 diabetes, the reduction was 17.3 percent.
The company said inaxaplin was generally safe and well tolerated in both cohorts. Vertex also said it had completed enrollment in the Phase 2/3 AMPLITUDE study and remained on track to report interim analysis results in early 2027.
